Search

Author/Creator Kannan, Meena

1. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Issue 7 (July 2022)

Authors:
Foley, John F; Defer, Gilles; Ryerson, Lana Zhovtis; Cohen, Jeffrey A; Arnold, Douglas L; Butzkueven, Helmut; Cutter, Gary; Giovannoni, Gavin; Killestein, Joep; Wiendl, Heinz; Smirnakis, Karen; Xiao, Shan; Kong, George; Kuhelj, Robert; Campbell, Nolan; van der Walt, Anneke; Dwyer, Christopher; Bu...
Journal:
Lancet neurology
Issue:
Volume 21:Issue 7(2022)
Page Start:
608
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search